NanoSphere Health Sciences Secures Patent For Groundbreaking Nanoparticle Delivery of Cannabis

Denver (July 24, 2018) -- NanoSphere Health Sciences LLC (CSE: NSHS) (OTC: NSHSF) has been awarded a breakthrough patent, granting the biotech innovator full ownership over the standardized delivery of cannabis into systemic circulation through phospholipid nanoparticle technology. The United States Patent and Trademark Office has issued US Patent No. 10,028,919 today, covering NanoSphere Health Sciences’ cannabinoid drug delivery system

Read More
Samuel TheilComment
NanoSphere Health Sciences Wins Prestigious Frost & Sullivan 2018 Technology Innovation Award

Nano-Biotechnology Firm Recognized for its Next-Generation Medical Delivery System in the Frost & Sullivan 2018 Best Practices Awards

DENVER (May 23, 2018) – NanoSphere Health Sciences INC (CSE: NSHS) (OTC: NSHSF), the nano-biotechnology company that has commercialized a patented delivery system known as the NanoSphere Delivery System™, has been awarded the 2018 Technology Innovation Award by Frost & Sullivan as part of the annual Best Practices Awards for North America. These awards recognize excellence across a number of fields and are the result of independent research conducted by Frost & Sullivan, which specializes in business growth partnerships.

Read More
Samuel TheilComment
NanoSphere Health Sciences and Vertical Companies™ Form Strategic Partnership to Launch Evolve Products in Arizona & California

Licensing agreement will bring the patented NanoSphere Delivery System™ to the world’s largest legal market this summer

DENVER (May 2, 2018)– NanoSphere Health Sciences INC (CSE: NSHS) (OTC: NSHSF), parent company of cannabis brand Evolve Formulas, has joined forces with Vertical™, the largest fully integrated company in the legal medical cannabis industry, to launch Evolve’s growing product line in Arizona and California this summer.

READ MORE

Read More
Samuel TheilComment
NanoSphere's Evolve Formulas Releases CBD Version of Game-Changing NanoSerum™

New product formula utilizes CBD, THC and resveratrol for rapid repair and rejuvenation with nanotechnology for the ultimate therapy

DENVER, April 30, 2018 /PRNewswire/ -- NanoSphere Health Sciences INC (CSE: NSHS) (OTC: NSHSF), parent company of cannabis brand Evolve Formulas, today announced the latest addition to its cannabis product line-up using NanoSphere Health's patented delivery technology. The new Transdermal NanoSerum™ CBD pen is now available with a desirable 10:1 ratio of CBD:THC. The product will be in Colorado dispensaries starting in mid-May.

READ MORE

Read More
Samuel TheilComment
Welcome to Cannabis 2.0: Nanotechnology Offers Next-Generation Marijuana Delivery

In only a brief period of time, the cannabis industry has achieved remarkable progress, bringing to market safer, more intelligent product offerings, backed by research and designed to not only enhance but transform the consumer experience. Science and biotechnology companies are increasingly breaking down barriers, fighting the stigma, and making important strides toward gaining widespread acceptance of marijuana as a legitimate medical tool and, more specifically, as a trusted alternative to harmful and addictive prescription opiates.

READ MORE

Read More
Samuel TheilComment
Are Transdermal the Future of Cannabis?

Chief Science Officer, Dr. Kaufman makes some thoughtful arguments about the speed of transdermal delivery.

However, these mainstream methods of consuming and administering marijuana are potentially problematic for a number of reasons. Fortunately, innovative new administration methods that deliver cannabinoids through the skin—using transdermals—or through the mucosa in the nose and mouth—using intranasal and intraoral products—are on the rise, offering promising solutions to the common issues associated with traditional cannabis delivery.

READ MORE

Read More
Kate Wells
Letter from Our Chairman

Dear Valued Shareholders,     

I would like to take this opportunity to outline the details of a significant milestone for NanoSphere Health Sciences and how this will impact the future of the company. We have been granted our landmark patent for the NanoSphere Delivery System™, which means we now officially have ownership of the biggest advancement in non-invasive medical delivery in over 25 years. A major thank you is in order to everyone who has come on this journey with us, especially those who have been here since the very beginning—from the challenging years of R&D through the pivotal point of commercialization to now, as we realize this new reality and lay the foundation for the bright future of this business. 

READ MORE

Read More
NanoSphere Health Sciences Awarded Breakthrough Patent for Disruptive Nanoparticle Delivery Platform

Landmark patent marks most significant advancement in over 25 years for non-invasive medical delivery system

Denver (March 27, 2018) – NanoSphere Health Sciences Inc (CSE: NSHS) (OTC: NSHSF) is pleased to announce that its flagship subsidiary, NanoSphere Health Sciences, LLC, has been granted Patent No. 9,925.149—which covers the core technology behind the production of the NanoSphere Delivery System™—by the United States Patent and Trademark Office.

READ MORE

Read More
Samuel TheilComment
NanoSphere Health Sciences’ Cannabis Brand Now Available in Over 100 Dispensaries in Colorado

Evolve Formulas’ Transdermal NanoSerum™ Continues to Expand

DENVER (March 7, 2018) – NanoSphere Health Sciences Inc. (CSE: NSHS/ OTC: NSHSF) cannabis product brand Evolve Formulas is now stocked in over 100 dispensaries throughout Colorado. The company’s pioneering product, Transdermal NanoSerum™, uses the NanoSphere Delivery System™ developed by the biotechnology firm to allow cannabis to enter systemic circulation within ten minutes for fast-acting, effective relief from pain, inflammation and anxiety. This milestone comes on the back of continuous growth, with the company recently signing a licensing agreement in California.

READ MORE

Read More
Samuel TheilComment
Evolve Formulas Expands Product Line with Return of 5ml NanoSerum™ Pen

20 Dose-Dispenser Provides Discrete and Hassle-Free Option for Evolve Customers

DENVER (DATE) – Back by popular demand, the 5ml Transdermal NanoSerum™ pen is now available in more than 90 dispensaries throughout Colorado. This compact product size contains 20 doses of NanoSerum™, each with 10mg of THC. The game-changing Evolve Formulas product immediately penetrates the skin following application to deliver direct-focused relief from pain, inflammation and anxiety.

READ MORE

Read More
Samuel TheilComment
Evolve Formulas Food Truck Event at Lightshade-Peoria Provides Meals for Those in Need

Innovative Biotech Company Teams Up With Dispensary and Charity Partners for Community Event

Denver (Feb 26, 2018) - Evolve Formulas supported one of Denver’s most vulnerable populations last week through a unique charity initiative. A Kitchen One-For-One food truck served up a variety of delicious menu items to Evolve customers at the Lightshade - Peoria dispensary. For every meal provided to Lightshade employees and customers, a meal will go to those in need. Approximately 800 meals will be provided to homeless members of the local community as a result of the initiative on Saturday, March 3.

READ MORE

Read More
Samuel TheilComment
NanoSphere Health Sciences Inc. (Formerly Corazon Gold Corp.) Announces Name Change, CSE Listing And Conversion Of $5.9m In Subscription Receipts

DENVER, Dec. 4, 2017 /PRNewswire/ -- NanoSphere Health Sciences Inc. (CSE: NSHS) ("NanoSphere") (formerly Corazon Gold Corp.) is pleased to announce a name change and listing on the Canadian Securities Exchange (the "CSE"), effective today.  NanoSphere's shares will commence trading tomorrow, December 5, 2017, under the symbol "NSHS".

READ MORE

Read More
Samuel TheilComment
Corazon and NanoSphere Announce Completion of $5.9 Million Financing and Merger

Corazon Gold Corp. (the “Company”) and NanoSphere Health Sciences, LLC (“NanoSphere”) are pleased to announce the closing of the Company’s private placement (the “Offering”) for gross proceeds of $5,905,685, and the completion of the Company’s acquisition (the “Acquisition”) of NanoSphere.  Based upon the CSE’s conditional listing approval, the Company will make its final submission for CSE listing in short order, and concurrently with its listing on the CSE will change its name to “NanoSphere Health Sciences Inc.” and effect a de-listing from the TSX Venture Exchange.

READ MORE

Read More
Samuel TheilComment